Here’s how analysts see Exact Sciences Corporation (NASDAQ:EXAS) after this past week.

Exact Sciences Corporation (NASDAQ:EXAS) Logo
Investors sentiment decreased to 1.26 in Q2 2019. Its down 0.03, from 1.29 in 2019Q1. It fall, as 31 investors sold Exact Sciences Corporation shares while 113 reduced holdings. 76 funds opened positions while 106 raised stakes. 108.62 million shares or 14.41% less from 126.90 million shares in 2019Q1 were reported.
Morgan Stanley holds 816,031 shares. The Massachusetts-based Granahan Investment Management Ma has invested 1.26% in Exact Sciences Corporation (NASDAQ:EXAS). Great Lakes Limited Liability Company reported 0.2% in Exact Sciences Corporation (NASDAQ:EXAS). 6,600 are owned by Virginia Retirement Et Al. Swiss Fincl Bank reported 410,000 shares. Bluestein R H & stated it has 0.02% in Exact Sciences Corporation (NASDAQ:EXAS). Bridges Invest Mngmt Incorporated accumulated 0.02% or 3,921 shares. Dimensional Fund L P reported 228,781 shares. Ls Inv Advsrs Llc invested in 0% or 674 shares. Gam Hldgs Ag stated it has 31,695 shares or 0.15% of all its holdings. Meeder Asset Mngmt owns 0.09% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 11,315 shares. Mogy Joel R Inv Counsel Incorporated accumulated 0.04% or 2,800 shares. Alpha Windward Ltd Com accumulated 247 shares. Df Dent And Commerce has 0.01% invested in Exact Sciences Corporation (NASDAQ:EXAS). Thompson Mgmt Inc holds 3.1% or 134,489 shares.

Exact Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Among 3 analysts covering EXACT Sciences (NASDAQ:EXAS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. EXACT Sciences has $14300 highest and $11000 lowest target. $124.33’s average target is 16.51% above currents $106.71 stock price. EXACT Sciences had 6 analyst reports since March 15, 2019 according to SRatingsIntel. The stock has “Buy” rating by Canaccord Genuity on Wednesday, May 1. The company was maintained on Tuesday, April 16 by UBS. As per Friday, April 12, the company rating was maintained by Goldman Sachs. The firm has “Buy” rating given on Wednesday, May 1 by UBS. The firm has “Buy” rating by UBS given on Thursday, August 1. Below is a list of Exact Sciences Corporation (NASDAQ:EXAS) latest ratings and price target changes.

01/08/2019 Broker: UBS Rating: Buy Old Target: $120.0000 New Target: $143.0000 Maintain
01/05/2019 Broker: UBS Old Rating: Buy New Rating: Buy Old Target: $115.0000 New Target: $120.0000 Maintain
01/05/2019 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $100.0000 New Target: $110.0000 Maintain
16/04/2019 Broker: UBS Old Rating: Buy New Rating: Buy Old Target: $109 New Target: $115 Maintain
12/04/2019 Broker: Goldman Sachs Old Rating: Buy New Rating: Buy New Target: $120 Maintain
15/03/2019 Broker: BidaskScore Rating: Buy Upgrade

The stock decreased 1.82% or $1.98 during the last trading session, reaching $106.71. About 1.03 million shares traded. Exact Sciences Corporation (NASDAQ:EXAS) has risen 100.54% since September 13, 2018 and is uptrending. It has outperformed by 100.54% the S&P500.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $13.77 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

More notable recent Exact Sciences Corporation (NASDAQ:EXAS) news were published by: which released: “The EXAS Paradox: Analysts Bullish But Forecast -1.26% Fall – Nasdaq” on July 15, 2019, also with their article: “Analysts Forecast 10% Gains Ahead For IWF – Nasdaq” published on September 10, 2019, published: “Exact Sciences (EXAS) Is Up 16.34% in One Week: What You Should Know – Nasdaq” on January 17, 2019. More interesting news about Exact Sciences Corporation (NASDAQ:EXAS) were released by: and their article: “Noteworthy Monday Option Activity: GOOG, EXAS, CMG – Nasdaq” published on April 29, 2019 as well as‘s news article titled: “Notable ETF Outflow Detected – VB, EXAS, ATO, BURL – Nasdaq” with publication date: June 12, 2019.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.